SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India inches up on completing stake sale in Granules-Biocause Pharmaceutical

04 Feb 2020 Evaluate

Granules India is currently trading at Rs. 146.40, up by 1.00 points or 0.69% from its previous closing of Rs. 145.40 on the BSE.

The scrip opened at Rs. 145.75 and has touched a high and low of Rs. 148.40 and Rs. 145.75 respectively. So far 18773 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 161.00 on 23-Jan-2020 and a 52 week low of Rs. 83.70 on 04-Feb-2019.

Last one week high and low of the scrip stood at Rs. 155.00 and Rs. 136.75 respectively. The current market cap of the company is Rs. 3714.56 crore.

The promoters holding in the company stood at 42.90%, while Institutions and Non-Institutions held 20.95% and 36.14% respectively.

Granules India has completed transaction of stake sale in Granules-Biocause Pharmaceutical, pursuant to which Granules-Biocause Pharmaceutical ceased to be the Joint Venture of the company. Earlier, the company had entered into an agreement with Hubei Biocause Heilen Pharmaceutical Co., Joint Venture Partner for sale of 33,000,000 equity shares of 1 RMB each fully paid-up held by the Company in Granules-Biocause Pharmaceutical for a consideration of RMB 109 million.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

 

Granules India Share Price

752.40 9.05 (1.22%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×